Dr. Donato is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
92 2nd Street
Hackensack, NJ 07601
Summary
- Dr. Michele Donato is an oncologist in Hackensack, NJ and is affiliated with Hackensack Meridian Health Hackensack University Medical Center. She received her medical degree from McGill University Faculty of Medicine and has been in practice 25 years. She also speaks multiple languages, including French. She specializes in hematologic oncology and is experienced in amyloidosis, hematologic oncology, myelodysplasia, myelofibrosis, and hodgkin's lymphoma.
Education & Training
- University of Massachusetts MBA, 2018 - 2022
- University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1995 - 1997
- McGill University Faculty of MedicineClass of 1992
Certifications & Licensure
- DC State Medical License 2004 - 2026
- NY State Medical License 2012 - 2026
- NJ State Medical License 2005 - 2025
- TX State Medical License 1997 - 2007
- PA State Medical License 1996 - 1998
- American Board of Internal Medicine Medical Oncology
- American Association of Physician LeadersCPE
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013-2014
Clinical Trials
- High-Dose Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer Start of enrollment: 1995 Sep 01
- Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia Start of enrollment: 2010 Apr 12
- Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma Start of enrollment: 2010 Apr 08
- Join now to see all
Publications & Presentations
PubMed
- cfDNA Chimerism and Somatic Mutation Testing in Early Prediction of Relapse After Allogeneic Stem Cell Transplantation for Myeloid Malignancies.Scott D Rowley, Maher Albitar, Melissa F Baker, Alaa Ali, Sukhdeep Kaur
Cancers. 2025-02-13 - Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, Aniko Szabo, Lawrence G Lum
Journal for Immunotherapy of Cancer. 2025-01-28 - Impact of Allogeneic Stem Cell Transplant on Safety and Outcomes of Chimeric Antigen Receptor T Cell (CAR-T) Therapy in Patients with Multiple Myeloma (MM).Ayrton Bangolo, Behzad Amoozgar, Lili Zhang, Vignesh K Nagesh, Imranjot Sekhon
Journal of Clinical Medicine. 2024-10-18
Abstracts/Posters
- Engraftment Syndrome in the Setting of Autologous Stem Cell Transplantation for Multiple Myeloma-a Single Institution Review of over 600 PatientsMichele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)Michele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Evomela¬ Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell TransplantationMichele L. Donato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Elevated IL-1Ra Levels in the Stem Cell Product Is Associated with the Development of Engraftment Syndrome Following Autologous Stem Cell Transplantation for the Treat...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Phase I/II Study of Escalating Doses of Thalidomide in Conjunction with Bortezomib and High Dose Melphalan As a Conditioning Regimen for Autologous Stem Cell Transplan...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- Bone Marrow Transplant Program Opens at Jersey Shore University Medical CenterAugust 19th, 2022
- 2022 N.J. Top Cancer Doctors Deliver Quality and Compassionate Care, Close to HomeJune 16th, 2022
- Philippines Again Extends COVID-19 Travel Ban on 10 Countries, Including UAE and OmanAugust 13th, 2021
- Join now to see all
Professional Memberships
- Member
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: